Adlarity is owned by Corium.
Adlarity contains Donepezil Hydrochloride.
Adlarity has a total of 7 drug patents out of which 0 drug patents have expired.
Adlarity was authorised for market use on 11 March, 2022.
Adlarity is available in system;transdermal dosage forms.
Adlarity can be used as a method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type.
The generics of Adlarity are possible to be released after 11 August, 2038.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10016372 | CORIUM | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
Jul, 2037
(14 years from now) | |
US11103463 | CORIUM | Methods for treating alzheimer's disease with donepezil transdermal system |
Jul, 2037
(14 years from now) | |
US9993466 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(14 years from now) | |
US10300025 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(14 years from now) | |
US10307379 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(14 years from now) | |
US10835499 | CORIUM | Systems and methods for long term transdermal administration |
May, 2038
(15 years from now) | |
US10966936 | CORIUM | Systems comprising a composite backing and methods for long term transdermal administration |
Aug, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Mar 11, 2025 |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2022
Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type
Dosage: SYSTEM;TRANSDERMAL
33
United States
11
Japan
9
Korea, Republic of
7
Australia
6
Canada
6
China
6
European Union
3
Russia
3
Singapore
3
Mexico
1
Israel
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic